Return-Path: Delivered-To: andrew@sterlingcal.com Received: from reseller401.webserversystems.com by reseller401.webserversystems.com with LMTP id OOrMH8CmD2iMNg8AchKAPA (envelope-from ) for ; Mon, 28 Apr 2025 11:03:12 -0500 Return-path: Envelope-to: andrew@sterlingcal.com Delivery-date: Mon, 28 Apr 2025 11:03:12 -0500 Received: from r68.info.wiley.com ([172.82.209.68]:55724) by reseller401.webserversystems.com with esmtps (TLS1.2) tls TLS_ECDHE_RSA_WITH_AES_256_GCM_SHA384 (Exim 4.98.1) (envelope-from ) id 1u9Qwq-00000004Cu4-0CZs for andrew@sterlingcal.com; Mon, 28 Apr 2025 11:03:12 -0500 DKIM-Signature: v=1; a=rsa-sha256; c=relaxed/relaxed; d=info.wiley.com; s=wileypublishing; t=1745856052; bh=Ws8ofrxoiXbVbWgZR+KXfYvf8PzuSFpeB5KIf2Ow2TU=; h=From:Subject:Date:To:MIME-Version:Message-ID:List-Unsubscribe: Content-Type; b=F5jL1Mop1SWpNZ+jogLyMLdN9I/JlAPuNh0NyjcokcYYPzpAsSsrCrcFoXcl2uP1l LTGcrGSgXakhnmtaDSnlWhZi3zVvRe9g9QqvydEIjPpCNJFDrk143hVSpupnw6kOd8 Ks69D/NmToHSXnL+jtwc2K2R85UM1IbnmZUTf1XsRKSJlv26HtgohGorjsujb3f8ok Qg4P/touwM3vVeYT/JSdFNmQS6fnk9M3iFloJUpIZCFI/gaKMkooq3JAD0Do+e8JiK YtDS/b5ufG5SOwxJzWQuTS6n3X4jkyZFSGsrHV1c2xqvBkAGu1dA3S82BMCEFgSwrC 9mR8yYNGAlNWA== X-MSFBL: /067QFnIgPntVcZruKkNXDRlQumXc1ACQOBGAYX0lkw=|eyJnIjoicHJvZC5qb2h ud2lsZXltYXJrZXRpbmdfOWZiYWY3ZjAtNTY3ZC00NWE5LWFiMmUtNDA4YzljNTZ hNjc1IiwiYiI6IndpbGV5cHVibGlzaGluZ18xNzIuODIuMjA5LjY4X3Byb2Quam9 obndpbGV5bWFya2V0aW5nXzlmYmFmN2YwLTU2N2QtNDVhOS1hYjJlLTQwOGM5YzU 2YTY3NSIsInIiOiJhbmRyZXdAc3RlcmxpbmdjYWwuY29tIiwicmNwdF9tZXRhIjp 7ICJpbiI6ICJ3aWxleXB1Ymxpc2hpbmdfbWlkX3Byb2Q3IiwgInIiOiAiYW5kcmV 3QHN0ZXJsaW5nY2FsLmNvbSIsICJtIjogImQ1NjQwYzg5LTI0ZDEtNDQ2Zi05MDE 3LTNlMjhjZGJmNzBlMyIsICJkIjogIjc4MzQ3MTQiLCAiaSI6ICIxQjZFMzRCODU yODJBMEFDMEE0OTBENDRAQWRvYmVPcmciIH19 Received: from [10.1.1.129] ([10.1.1.129:36065] helo=r67.info.wiley.com) by or2-prod1-mta-i-0c9fbd93457672aa6 (envelope-from ) (ecelerity 4.4.1.20033 r(msys-ecelerity:tags/4.4.1.0^0)) with ESMTP id 82/A9-24627-436AF086; Mon, 28 Apr 2025 16:00:52 +0000 From: "Wiley" Subject: =?windows-1252?Q?Unlock_the_secrets_of_sequence_variants_in_biot?= =?windows-1252?Q?herapeutics_=96_Join_our_webinar!?= Date: Mon, 28 Apr 2025 12:00:11 -0400 To: Reply-To: "Wiley" MIME-Version: 1.0 X-mailer: nlserver, Build 8.6.4 Message-ID: List-Unsubscribe: Content-Type: text/html; charset="windows-1252" Content-Transfer-Encoding: quoted-printable X-Spam-Status: No, score=-4.0 X-Spam-Score: -39 X-Spam-Bar: ---- X-Spam-Flag: NO

If you are unable to view this message correctly, click here

You=92re invited

Dive into the world of biotherapeutics = with our upcoming webinar! We'll explore the impact of sequence variants on= protein therapeutics and reveal cutting-edge detection methods. Learn from= real-world case studies and gain valuable insights that will enhance your = understanding and expertise.

What to expect:

•	Understand the impact of sequence= variants on drug efficacy, stability, and immune responses.
•	Discover detection methods using = icIEF-UV/MS and EAD-enabled LC/MS techniques.
•	Explore a real-world case study o= n identifying and mitigating a sequence variant.

Ready to get = started=3F Register now to secure your spot!

REGISTER NOW

Speaker information

Kristen Nields, Principal Scientist
Johnson & Johnson Innovative Medicine

Kristen Nields is the Principa= l Scientist in the Cell and Developability Group at Johnson & Johnson Innov= ative Medicine with 20+ years of experience in the biopharma industry. She = specializes in bridging mass spectrometry and product quality functions to = enhance communication. Kristen is recognized for developing innovative anal= ytical methods within the Johnson & Johnson organization to close product k= nowledge gaps.

Riley Schaefer, Co-Op Scientist II
Johnson & Johnson Innovative Medicine

Riley Schaefer is a recent hon= ors graduate from St. Joseph=92s University with a B.S. in Biochemistry. He= currently works as the Analytical Cell Engineering & Development Co-Op at = Johnson & Johnson Innovative Medicine. His focus is on developing analytica= l methods to assess the biophysical product quality of monoclonal and multi= -specific antibodies for the purpose of engineering an array of manufacturi= ng cell lines.

This virtual seminar has been made possible t= hrough sponsorship from Sciex.

= ; &nb= sp; =